Ceft-to-Ceft Study: Real-Life Experience with Ceftaroline and Ceftobiprole in Treatment of the Principal Infectious Syndromes in a Spanish Multicenter Hospital Cohort
Daniel Arnés García, Inés Pitto-Robles, Jorge Calderón Parra, Marina Calvo Salvador, Carmen Herrero Rodríguez, Laura Gisbert, Carmen Hidalgo-Tenorio, Masafumi Seki · 2023
Read Ceft-to-Ceft Study: Real-Life Experience with Ceftaroline and Ceftobiprole in Treatment of the Principal Infectious Syndromes in a Spanish Multicenter Hospital Cohort by Daniel Arnés García, Inés Pitto-Robles, Jorge Calderón Parra, Marina Calvo Salvador, Carmen Herrero Rodríguez, Laura Gisbert, Carmen Hidalgo-Tenorio, Masafumi Seki (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10740782.txt.
Description
Daniel Arnés García and co-authors compared, in a 2023 Spanish study, two newer antibiotics in real hospital use. Ceftaroline and ceftobiprole both fight stubborn Gram-positive germs. Head-to-head real-life data across the main infection types was thin.
Records from many hospitals covered 227 patients on the first drug and 212 on the second, in wards and home infusion care. The first group skewed younger and sicker, with more blood infections, heart valve infections, and ventilator lung infections. Their therapy was more often targeted and combined with other drugs. The second drug served a broader, less severe mix. The authors read the split as a sign of how clinicians steer each drug in practice, rather than a pure contest of strength.
Catalog record
| CREATOR | Daniel Arnés García, Inés Pitto-Robles, Jorge Calderón Parra, Marina Calvo Salvador, Carmen Herrero Rodríguez, Laura Gisbert, Carmen Hidalgo-Tenorio, Masafumi Seki |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 53 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |